Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Patients with depression tend to have a higher prevalence of smoking as well as increased
severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that
demonstrated its efficacy and tolerability have not included subjects with depression. This
smoking cessation study focuses on the depressed population and will assess the efficacy and
safety of varenicline.